Nutriband Inc., a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has completed the registration requirements to extend its Chinese patent to Macao for its patent entitled, “Abuse and Misuse Deterrent Transdermal

CEO Gareth Sheridan has published a letter to shareholders highlighting the company’s achievements in 2024 and the outlook for 2025. nutriband.com/post/nutriband… #ntrb #nutriband #nutribandnews

The Annual Meeting of Stockholders (the “Annual Meeting”) of Nutriband Inc., a Nevada corporation (the “Company”), will be held at 400 West Church Street, City National Hourglass Room, Orlando, FL 32801, on Thursday, January 23, 2025, at 10:00 A.M. (local time) for the following

Nutriband Inc., a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) on February 3, 2025 for patent application 18/369,241,

Nutriband Inc., a developer of transdermal pharmaceutical products, today announced World and European Wrestling Gold medalist and Olympic Silver medalist Anastasia Nichita has been appointed to its Product Advisory Board to expand the Nutriband Brand and promote it’s over the

Nutriband Inc. today announced that it has signed an addendum to the Commercial Development and Clinical Supply Agreement for its lead product, Aversa™ Fentanyl, that it has in place with its partner, Kindeva Drug Delivery, a leading global contract development and manufacturing

The Company intends to use the Associate partnership to build visibility for its brands such as AI Tape which is manufactured locally in the Charlotte area. “We are very excited to partner with an organization such as Charlotte FC as an Associate Partner. Manufacturing many of

In the Established category, the finalists are: Karl Fitzpatrick of Chevron College; Derek Foley Butler of Grid Finance; James Kelly of LMH Engineering Group; William McColgan of McColgans Quality Foods; Gareth Sheridan of Nutriband Inc; Terry Hughes of Pivotal; Larry Bass of

Nutriband Inc. today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and milestones through 2024 and the potential outlook for 2025. The full content of the letter is available at the link below.

Nutriband is continuing to expand its kinesiology tape output through its Pocono Pharma subsidiary, with a continued focus on penetration pricing to gain a foothold with some of the industry’s largest brands. The Company produced a record first quarter reporting revenue of

Nutriband Inc. today announced that CEO, Gareth Sheridan will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on Thursday, June 5th at 4PM Eastern Standard Time. The formal presentation will feature a fireside style Q&A session with questions welcome

Nutriband Inc. a company engaged in the development of prescription transdermal pharmaceutical products, today announced that the United States Patent and Trademark Office (USPTO) issued patent number 12,318,492 on June 3, 2025, entitled "Abuse and Misuse Deterrent Transdermal

Nutriband Inc. a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has completed commercial manufacturing process scale-up for its lead product, Aversa™ Fentanyl, with Kindeva, a leading global contract development

“Being added to the four Russell indexes is a great honor for us as a company as we continue to strive towards building shareholder value and progressing the development of our AVERSA pipeline and in particular AVERSA Fentanyl which has the potential to reach peak annual US sales

Shareholders of record on July 25th 2025 will receive one preferred share for every four shares of common stock held. The pay date for shareholders to receive their new issuance will be August 5th. Each preferred share will be convertible to one share of common stock following

The United States Food and Drug Administration (US FDA) has granted a Type C Meeting for its lead product, AVERSA™ FENTANYL (abuse deterrent fentanyl transdermal system). The purpose of the meeting is to specifically provide feedback on the Chemistry, Manufacturing, and Controls

Nutriband Inc. has announced that Company CEO, Gareth Sheridan will be stepping aside from his role for three months to enter the Irish Presidential election. The Nomination Hearings followed by the Election will take place over the course of September and October. During this